Rheumatology Network Newsletter

To view this email as a web page, click here.

A Skin Rash and Clues that Lead to a Serious Rheumatic Condition

Reporting in the Oct. 14 issue of The American Journal of Medicine, Kristopher Ahn, M.D., and Rukma Govindu, M.D., describe a case of an otherwise healthy 36-year-old African American woman who presents to the emergency department for treatment of a long-lasting skin rash. As her ED visit unfolds, it turns into a complicated, challenging, difficult to diagnose case. Learn more in this featured case study.

Anakinra Bests TNF Inhibitors in RA Patients with Type 2 Diabetes

IL-1 inhibition with anakinra was more effective than TNFi treatment for improving glycemic and inflammatory parameters in patients with rheumatoid arthritis and type 2 diabetes, say researchers writing in PLOS Medicine last month.

Ixekizumab Bests Adalimumab at 24 Weeks in Psoriatic Arthritic Skin, Joint Symptoms

Ixekizumab was superior to adalimumab at 24 weeks in a head-to-head trial evaluating both skin and joint symptoms in patients with psoriatic arthritis and inadequate response to csDMARDs, say researchers writing in Annals of the Rheumatic Diseases last month.

This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply. Please use the links provided if you have questions or concerns regarding this email or your subscription.